Pubfacts - Scientific Publication Data
  • Categories
  • |
  • Journals
  • |
  • Authors
  • Login
  • Categories
  • Journals

Search Our Scientific Publications & Authors

Publications
  • Publications
  • Authors
find publications by category +
Translate page:

Prevalence of age-related macular degeneration in a large European cohort: results from the population-based Gutenberg Health Study.

Authors:
Christina A Korb Ulrike B Kottler Christian Wolfram René Hoehn Andreas Schulz Isabella Zwiener Philipp S Wild Norbert Pfeiffer Alireza Mirshahi

Graefes Arch Clin Exp Ophthalmol 2014 Sep 25;252(9):1403-11. Epub 2014 Feb 25.

Department of Ophthalmology, University Medical Center, Johannes Gutenberg-University Mainz, Langenbeckstr.1, 55131, Mainz, Germany,

Background: The aim of this study was to describe the sex- and age-specific prevalence of age-related macular degeneration (AMD) and its correlation with urban or rural residence in a large and relatively young European cohort.

Methods: We evaluated fundus photographs from participants in the Gutenberg Health Study (GHS), a population-based, prospective, observational, single-centre study in the Rhineland-Palatine region in midwestern Germany. The participants were 35-74 years of age at enrolment. The fundus images were classified as described in the Rotterdam Study and were graded independently by two experienced ophthalmologists (CK and UBK) based on the presence of hard and soft drusen, retinal pigmentary abnormalities, and signs of atrophic or neovascular age-related macular generation (AMD).

Results: Photographs from 4,340 participants were available for grading. Small, hard drusen (<63 μm, stages 0b and 0c) were present in 37.4% of participants (95% confidence interval [CI], stage 0b, 31.6% [30.3-33.7]; stage 0c, 5.8% [5.1-6.5]). Early AMD (soft drusen, pigmentary abnormalities, stages 1-3) was present in 3.8% of individuals in the youngest age group (35-44 years) (95% CI, stage 1a, 0.4% [0.3-0.5%]; stage 1b, 3.2% [2.9-3.5%]; stage 2a, 0.1% [0.1-0.2%]; stage 2b, 0% [0-0.0%]; stage 3, 0.1% [0.1-0.2%]), whereas late AMD (stages 4a and 4b) did not appear in the youngest age group. In all age groups, signs of early AMD were detected in 11.9% of individuals (stage 1a, 2.1% [1.7-2.6]; stage 1b, 8.0% [7.2-8.8]; stage 2a, 1.0% [0.7-1.3]; stage 2b, 0.5% [0.3-0.7]; stage 3, 0.3% [0.2-0.6]). Late AMD (geographic atrophy or neovascular AMD) was found in 0.2% of individuals (stage 4a, 0.1 % [0.0-0.2]; stage 4b, 0.1% [0.0-0.2]). AMD increased significantly with age (odds ratio [OR], 1.09; 95% CI, 1.08-1.10). Sex, iris colour, and residence (rural vs. urban) were not associated with different rates of AMD.

Conclusions: In this study, the prevalence of AMD increased dramatically with age; however, although AMD is usually thought to occur after age 50, signs of early AMD were found in 3.8% of individuals in the youngest age group (younger than 45 years). This population-based sample is the first to provide substantial epidemiologic data from a large German cohort, including data on macular degeneration in younger age groups and incidence data after recall.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00417-014-2591-9DOI Listing
September 2014

Publication Analysis

Top Keywords

age-related macular
12
macular degeneration
8
health study
8
gutenberg health
8
prevalence age-related
8
study
5
study rhineland-palatine
4
single-centre study
4
rhineland-palatine region
4
region midwestern
4
pigmentary abnormalities
4
germany participants
4
midwestern germany
4
observational single-centre
4
abnormalities signs
4
prospective observational
4
participants gutenberg
4
photographs participants
4
fundus photographs
4
ubk based
4

Altmetric Statistics


Show full details
11 Total Shares
6 News Outlets
5 Tweets
11 Citations

Similar Publications

Assessing the Quality, Content, and Readability of Freely Available Online Information for Patients Regarding Age-Related Macular Degeneration.

Authors:
Amy Kloosterboer Nicolas Yannuzzi Nicole Topilow Nimesh Patel Ajay Kuriyan Jayanth Sridhar

Semin Ophthalmol 2021 Mar 1:1-6. Epub 2021 Mar 1.

Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, United States of America.

: One of the top ten causes of disability in the United States is vision loss, primarily due to age-related eye diseases such as age-related macular degeneration. With an aging population, the number of people affected by this condition is expected to rise. Patients increasingly turn to the internet for health-related information, but no standard exists across published websites. Read More

View Article and Full-Text PDF
March 2021
Similar Publications

7-ketocholesterol induces endothelial-mesenchymal transition and promotes fibrosis: implications in neovascular age-related macular degeneration and treatment.

Authors:
Haibo Wang Aniket Ramshekar Eric Kunz M Elizabeth Hartnett

Angiogenesis 2021 Feb 28. Epub 2021 Feb 28.

The John A Moran Eye Center, University of Utah, 65 Mario Capecchi Drive, Salt Lake City, UT, USA.

Oxidized cholesterols and lipids accumulate in Bruch's membrane in age-related macular degeneration (AMD). It remains unknown what causal relationship exists between these substances and AMD pathophysiology. We addressed the hypothesis that a prevalent form, 7-ketocholesterol (7KC), promotes choroidal endothelial cell (CEC) migration and macular neovascularization in AMD. Read More

View Article and Full-Text PDF
February 2021
Similar Publications

Gene-based analysis of bi-variate survival traits via functional regressions with applications to eye diseases.

Authors:
Bingsong Zhang Chi-Yang Chiu Fang Yuan Tian Sang Richard J Cook Alexander F Wilson Joan E Bailey-Wilson Emily Y Chew Momiao Xiong Ruzong Fan

Genet Epidemiol 2021 Mar 1. Epub 2021 Mar 1.

Department of Biostatistics, Bioinformatics, and Biomathematics, Georgetown University Medical Center, Washington, District of Columbia, USA.

Genetic studies of two related survival outcomes of a pleiotropic gene are commonly encountered but statistical models to analyze them are rarely developed. To analyze sequencing data, we propose mixed effect Cox proportional hazard models by functional regressions to perform gene-based joint association analysis of two survival traits motivated by our ongoing real studies. These models extend fixed effect Cox models of univariate survival traits by incorporating variations and correlation of multivariate survival traits into the models. Read More

View Article and Full-Text PDF
March 2021
Similar Publications

The role of gap junctions in cell death and neuromodulation in the retina.

Authors:
Gergely Szarka Márton Balogh Ádám J Tengölics Alma Ganczer Béla Völgyi Tamás Kovács-Öller

Neural Regen Res 2021 Oct;16(10):1911-1920

János Szentágothai Research Centre, University of Pécs, Pécs; Retinal Electrical Synapses Research Group, National Brain Research Program (NAP 2.0), Hungarian Academy of Sciences, Budapest; Medical School, University of Pécs, Pécs, Hungary.

Vision altering diseases, such as glaucoma, diabetic retinopathy, age-related macular degeneration, myopia, retinal vascular disease, traumatic brain injuries and others cripple many lives and are projected to continue to cause anguish in the foreseeable future. Gap junctions serve as an emerging target for neuromodulation and possible regeneration as they directly connect healthy and/or diseased cells, thereby playing a crucial role in pathophysiology. Since they are permeable for macromolecules, able to cross the cellular barriers, they show duality in illness as a cause and as a therapeutic target. Read More

View Article and Full-Text PDF
October 2021
Similar Publications

Evaluation of Port Delivery System with ranibizumab for the treatment of neovascular age-related macular degeneration.

Authors:
Annika J Patel Dante J Pieramici Nika Bagheri

Ther Deliv 2021 Mar 1. Epub 2021 Mar 1.

California Retina Consultants & Research Foundation, Santa Barbara, CA 93103, USA.

Current treatment of neovascular age-related macular degeneration involves periodic intravitreal injections of anti-VEGF medication, creating a burden to patients and physicians, resulting in nonadherence to recommended dosing schedules. The Port Delivery System with ranibizumab offers a long-term solution that involves implantation of a device into the pars plana and provides continuous release of anti-VEGF medication into the vitreous, thus requiring fewer office visits. The Port Delivery System has demonstrated comparable visual and anatomic outcomes to monthly injections and shows promise in alleviating the patient burden in the treatment of neovascular age-related macular degeneration, making possible better long-term real-world visual outcomes. Read More

View Article and Full-Text PDF
March 2021
Similar Publications
© 2021 PubFacts.
  • About PubFacts
  • Privacy Policy
  • Sitemap